---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-056770"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:46:26.743201+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# UroGen presents at TD Cowen conference; no material updates provided

## Summary
- Presentation furnished as Exhibit 99.1 for TD Cowen 44th Annual Health Care Conference on March 4, 2024.
- Title slide states: 'Developing Innovative Medicines to Treat Urothelial Cancers'.
- No specific financial, clinical, or guidance data included in the filing or exhibit excerpt.
- Filing is procedural Regulation FD disclosure; no new material events reported.

## SEC filing metadata
- accession: 0001193125-24-056770
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312524056770/0001193125-24-056770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312524056770/d743593d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-056770
- JSON: https://secwatch.observer/filing/0001193125-24-056770.json
- Plain text: https://secwatch.observer/filing/0001193125-24-056770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.